echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Biosensors can detect brain tumors with less than a drop of blood

    Biosensors can detect brain tumors with less than a drop of blood

    • Last Update: 2022-10-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      

    According to the National Cancer Institute, despite significant progress, the death rate from brain tumors remains high, with a 5-year survival rate of 36 percent
    .
    A more accurate diagnosis may improve the situation, but tissue biopsies are invasive and may miss important information
    about tumor composition.
    At the same time, image-based methods do not provide sufficient sensitivity and resolution
    .
    Now, the researchers report in the journal ACS Nano that they have developed a biosensor that could help doctors accurately diagnose brain cancer
    from a one-minute blood sample.

    To effectively treat brain cancer, doctors need to confirm not only the presence of malignancies, but also where it originated (primary tumor) or metastasized from other organs to the brain (secondary tumor
    ).
    Doctors also need to know where the tumor is
    in the organ.
    Because existing diagnostic techniques do not require surgery or painful spinal punctures to accomplish this feat, Bo Tan and his colleagues wanted to develop a noninvasive test
    that uses a small amount of serum.

    The researchers used a high-intensity laser beam to form a three-dimensional nickel-nickel oxide nanolayer
    on a nickel chip.
    This process produces an ultra-sensitive biosensor that allows them to detect trace amounts of tumor-derived substances, such as nucleic acids, proteins, and lipids, that pass through the blood-brain barrier and enter circulation
    .
    The sensor detects these components using a method called surface-enhanced Raman spectroscopy, which generates a molecular map or fingerprint
    for each sample.
    The researchers then analyzed the data with the DEEP neural network to find evidence of brain tumors, determine their type, and predict their location
    in the brain.

    Using a liquid biopsy platform, researchers can detect brain cancer from 5 microliters of serum and distinguish
    it from breast, lung and coloral cancers with 100% specificity and sensitivity.
    They had similar success
    in distinguishing between primary brain tumors and secondary brain tumors that metastasized to the brain (metastases from the lungs or mammary glands to the brain).
    The profile analysis also allowed the researchers to determine with 96 percent accuracy which of the nine brain regions the tumor was located
    .
    The non-invasive nature of this test should allow health care professionals to monitor the development of cancer over time so they can make better treatment decisions
    , the researchers said.

    DEEP Surveillance of Brain Cancer Using Self-Functionalized 3D Nanoprobes for Noninvasive Liquid Biopsy

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.